This Plain Language Summary of Publication article (PLSP) from Postgraduate Medicine discusses an article about sodium-glucose cotransporter 2 (SGLT2) inhibitors and their use in treating chronic kidney disease (CKD). Originally developed for type 2 diabetes management, research has revealed these medications offer significant kidney and heart protection for CKD patients, regardless of whether they have diabetes. The article explains the physiological mechanisms of SGLT2 inhibitors and outlines their specific benefits for people with chronic kidney disease.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative review’ and was published in Postgraduate Medicine.

Visit Taylor & Francis Online using the link to read the original article.